Molecular Targets for Cancer Therapy
Organizer(s): Sara A. Courtneidge and Frank McCormickDate: January 06 - 11, 2005
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
Recent years have seen the approval of several targeted cancer therapeutics. For example, Herceptin (which targets Her2) is used for the treatment of some breast cancers, Gleevec (targeting Bcr-Abl and c-Kit) for chronic myelogenous leukemia and gastrointestinal stromal tumors, and Iressa (targeting the EGF receptor) for lung cancer. These new drugs highlight that we have entered an exciting era, in which cancer therapy involves identifying and targeting key molecular drivers of the disease. Yet many very important questions remain, including: Which are the best molecular targets? What is the role of combination therapy? And anti-angiogenesis therapy? Which animal models are most predictive of the human disease? Should we be targeting 'cancer stem cells'? The goal of this meeting is to bring together leaders from all areas of cancer research to discuss these issues surrounding the identification of new molecular targets, and the generation and testing of therapeutics directed against them.
Discounted Abstract Deadline: September 15 2004
Discounted Registration Deadline: November 8 2004
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Merck Research Laboratories